Login to Your Account



House Inquiry Into ImClone Could Lead To FDA Changes

By Kim Coghill


Tuesday, June 18, 2002
WASHINGTON - A congressional investigation into ImClone Systems Inc.'s handling of the cancer drug Erbitux eventually could end in a more transparent FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription